LDS/Medical Tests/B-Cell CD40 Expression by Flow Cytometry, Blood

B-Cell CD40 Expression by Flow Cytometry, Blood

The CD40–CD40 ligand (CD40L) interaction plays a central role in both humoral and cellular immune responses. CD40 is a costimulatory receptor highly expressed on B-cells, dendritic cells, macrophages, and other antigen-presenting cells. Upon antigen recognition, activated T helper cells express CD40L (CD154), which binds to CD40 on B-cells, initiating an intracellular signaling cascade through TRAF adapter proteins and activating key pathways such as NF-κB and MAPK. This interaction promotes T cell–dependent B-cell activation, proliferation, antibody production, and immunoglobulin class switching. Beyond B-cell regulation, CD40 signaling enhances the antigen-presenting capacity of dendritic cells and macrophages, promotes cytokine release, and contributes to immune modulation in inflammation, infection, and malignancy. In oncology, CD40/CD40L signaling is a promising therapeutic target. CD40 agonists enhance anti-tumor immunity, whereas blocking antibodies can downregulate autoimmune responses or prevent transplant rejection. The measurement of B-cell CD40 expression by flow cytometry provides valuable information on immune competence, assists in identifying candidates for immunotherapy targeting this pathway, and supports precision-medicine approaches across immune, autoimmune, and oncologic disorders. Genetic variants that disrupt CD40 expression lead to defective immunoglobulin class switching from IgM to IgG or IgA, resulting in hyper-IgM type 3 (HIGM3) syndrome. This rare autosomal recessive disorder (<1% of all HIGM syndromes) presents in infancy or early childhood with recurrent infections, low IgG/IgA, and markedly elevated IgM. Flow cytometry in affected patients shows an absence of CD40 expression on B-cells.
  • As and aid in the diagnosis and monitoring of hyperimmunoglobulin M syndromes (hyper-IgM type 3, CD40 deficiency) syndrome
  • Aid in the diagnosis of other immunodeficiencies (Common variable immunodeficiency)
  • Aid in the diagnosis of lymphomas (diffuse large B-cell lymphoma, Burkitt lymphoma)

The assay qualitatively determines CD40 expression on B-cells.

Normal: Presence of CD40 expression on the majority of B-cells

Abnormal: Absence or markedly reduced CD40 expression, consistent with hyper-IgM type 3 syndrome

This is a screening test; molecular confirmation by CD40 gene sequencing is required for definitive diagnosis and identification of pathogenic variants.

Note: this assay differs from CD40L expression testing, which is used to diagnose X-linked hyper-IgM syndrome.

Present (Presence of CD40 on B-cell surface)

Flow cytometry.

Specimen: EDTA (Lavender-top) vial.

Stability

  • Ambient: 72 hrs.
  • Refrigerated: 3 days.
  • Frozen: unacceptable
CD40 gene analysis (sequencing), serum immunoglobulins, serum IgM, CBC, lymphocyte subset analysis, lymph node biopsy.
3 to 4 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login